Licochalcone A is extracted from licorice, chalcone compounds are widely discoverd in nature in a flavonoid. The main presence and expansion of glycyrrhiza, stem extraction, the content of about 0.416%, while the leaves and seed species without the presence of licorice Chalcone (TLC). And the structure is more complex, synthetic route is relatively long, need to use expensive reagents, so the synthesis cost is much higher than the natural extraction cost, so now the licorice Chalcone are basically natural products.
Trade Name: Shaanxi Huatai Bio-fine Chemical Co., Ltd.
Common Name: Licochalcone A
CAS No.: 58749-22-7
Molecular Formula: C21H22O4
Characteristics: Reddish brown powder
Solubility: Dissolved in ethanol, 1,3-butanediol. Do not dissolved in water
Specification: Cosmetic grade
Category: Skin Care
Features: Anti-viral, anti-inflammatory, anti-bacterial, anti-parasitic, antiviral and other biological activities. Licochalcone A is a kind of promising drug template. The results showed that the pharmacological activities of chalcone compounds are wide, safe, simple and convenient preparation is a good drug development lead. Especially against Gram-positive bacteria have significant effects, and some of the role of compounds and gentamicin effect of considerable.
Typical Dosage: 1‰-5‰
Packing: 1kg aluminum foil bag
Transport: Non-hazardous cargo(IMO/IATA)
Remarks: Safety and efficacy report available upon request.
Product feature application
Thirty-two test subjects with mild to moderate rosacea used the skin care regimen daily for 8 weeks. Clinical assessment of erythema, subjective irritation and clinical photography were performed at baseline and after 4 and 8 weeks. Additionally, a quality-of-life questionnaire was filled out by the test subjects at baseline and week 8. The subjects completed a self-assessment questionnaire on product properties after 4 and 8 weeks of product use.
Clinical assessments and subject response confirmed very good tolerability of the regimen, a statistically significant improvement in clinical grading for erythema and tactile roughness at weeks 4 and 8 and on telangiectasia at week 8 when compared to baseline scores. A statistically significant improvement in facial redness (a*) values, based on the L*a*b* colorimetric system, was determined at week 4 and 8 in comparison to baseline. No difference in corneometric measurement was detected at week 4 and 8 compared to baseline. Therefore, the daily use of skin care products containing LicA and SymSitive in patients with rosacea improves the overall skin appearance and the quality of life of these patients.
1. 1kg with double plastic container inside/Aluminum foil bag outside.